Search

Displaying results 2341 - 2350 of 5451 in total
  1. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  2. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Tridihexethyl is an antimuscarinic, a...

  3. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets. Evidence increasingly poin...

    Synonyms: IMMUNOGLOBULIN G4-LAMBDA, ANTI-(HOMO SAPIENS MANNAN-BINDING LECTIN SERINE PROTEASE 2 (MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN
  4. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with cardiovascular risk, and it … [A229278] In February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia

  5. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    It is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  6. Drug

    Queuine

    go.drugbank.com/drugs/DB14732
    ExperimentalNutraceutical

    All eukaryotic organisms, including humans, transform queuine to queuosine by placing it in the wobble position (anticodon) of several tRNAs including aspartic acid, asparagine, histidine, and tyrosine … Endogenously, it has been determined that queuine contributes to generating various important biochemicals like tyrosine, serotonin, dopamine, epinephrine, norepinephrine, nitric oxide, lipids, and others

  7. Drug

    Levobupivacaine

    go.drugbank.com/drugs/DB01002
    ApprovedInvestigationalWithdrawn

    When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. … It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine.

    Products: CHIROCAINE 5.0 MG/ML, CHIROCAINE INJECTION 5 mg/ml
  8. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. … [A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women.

  9. Drug

    Amaranthus retroflexus whole

    go.drugbank.com/drugs/DB10930
    Approved

    Amaranthus retroflexus whole allergenic extract is used in allergenic testing.

    Mixtures: Treatment Set TS345380
  10. Drug

    Etorphine

    go.drugbank.com/drugs/DB01497
    ExperimentalIllicitVet approved

    In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.